Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Maxim Group to hold a virtual conference » 08:58
05/05/20
05/05
08:58
05/05/20
08:58
APM

Aptorum Group

$3.25 /

+ (+0.00%)

, ARDS

Aridis Pharmaceuticals

$7.29 /

+0.885 (+13.83%)

, ARMP

Armata Pharmaceuticals

$3.49 /

-0.01 (-0.29%)

, CDTX

Cidara Therapeutics

$2.91 /

+0.15 (+5.43%)

, CFRX

ContraFect

$6.71 /

+0.3 (+4.68%)

, INO

Inovio

$11.26 /

+1.01 (+9.85%)

, MTNB

Matinas BioPharma

$0.71 /

-0.0345 (-4.63%)

, SCYX

Scynexis

$0.90 /

-0.0509 (-5.36%)

Maxim Group Infectious…

Maxim Group Infectious Disease Virtual Conference will be held on May 5 at 10 am. Webcast Link

ShowHide Related Items >><<
APM Aptorum Group
$3.25 /

+ (+0.00%)

ARDS Aridis Pharmaceuticals
$7.29 /

+0.885 (+13.83%)

02/19/20 Roth Capital
Aridis Pharmaceuticals initiated with a Buy at Roth Capital
01/27/20 Cantor Fitzgerald
Cantor sees 'meaningful' coronavirus opportunity for Aridis Pharmaceuticals
12/30/19
Fly Intel: Top five analyst actions
12/30/19 H.C. Wainwright
Aridis Pharmaceuticals initiated with a Buy at H.C. Wainwright
ARMP Armata Pharmaceuticals
$3.49 /

-0.01 (-0.29%)

02/06/20 Maxim
Armata Pharmaceuticals initiated with a Buy at Maxim
02/06/20 Maxim
Armata Pharmaceuticals initiated with a Buy at Maxim
01/29/20 H.C. Wainwright
Armata investment removes significant overhang, says H.C. Wainwright
10/31/19 H.C. Wainwright
Armata Pharmaceuticals price target raised to $9.50 from $7 at H.C. Wainwright
CDTX Cidara Therapeutics
$2.91 /

+0.15 (+5.43%)

03/10/20 Maxim
Cidara Therapeutics initiated with a Buy at Maxim
03/10/20 Maxim
Cidara Therapeutics initiated with a Buy at Maxim
01/27/20 Cantor Fitzgerald
Street underappreciates Cidara's Cloudbreak AVCs, says Cantor Fitzgerald
12/04/19 WBB Securities
Cidara Therapeutics upgraded to Buy from Speculative Buy at WBB Securities
CFRX ContraFect
$6.71 /

+0.3 (+4.68%)

10/02/19 Piper Sandler
Piper says design differentiates ContraFect trial from other antibiotic studies
06/11/19 Maxim
ContraFect initiated with a Buy at Maxim
INO Inovio
$11.26 /

+1.01 (+9.85%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
MTNB Matinas BioPharma
$0.71 /

-0.0345 (-4.63%)

03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
01/24/20
Fly Intel: Top five analyst initiations
SCYX Scynexis
$0.90 /

-0.0509 (-5.36%)

07/31/19 Aegis
Scynexis initiated with a Buy at Aegis
05/28/19 Canaccord
Scynexis weakness a buying opportunity, says Canaccord
Hot Stocks
Aptorum Group provides operational, clinical update amid COVID-19 outbreak » 08:14
04/29/20
04/29
08:14
04/29/20
08:14
APM

Aptorum Group

$3.35 /

-0.11 (-3.18%)

Aptorum Group's…

Aptorum Group's operational plans remain on track. In particular, the recently announced updates on SACT-1 and ALS-4 remain on track for its pre-IND preparation work. The company will continue to target IND submission in the second half of 2020, subject to regulatory review of the IND application. With the additional capital raised in February, the company is also on track to expand strategic initiatives including the discovery and development pipeline such as the recently announced initiative SACT-COV19 and additional Smart-Act platform projects being SACT-2 and SACT-3, which will be announced in due course. The company, together with the distributor, is also focused on the distribution of the recently announced non-hormonal based Dioscorea opposita bioactive nutraceutical supplement targeting woman's health during the menopausal or post-menopausal cycles. In light of the global coronavirus situation, the company would like to report that its day-to-day operations continue as normal. In March, Aptorum Group initiated an additional R&D program targeting the coronavirus group. The company has completed initial screening under our existing Smart-ACT platform, a repurposed and new drug discovery platform, to select at least three potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19, out of a library of more than 2,600 small drug molecules that were previously approved for other indications. Announced further positive data from the current investigational new drug, or IND-enabling studies for ALS-4, a small drug molecule candidate for the treatment of infections caused by Staphylococcus aureus. Subject to positive completion of the current studies, Aptorum Group targets to submit IND for ALS-4 in the second half of 2020 and commence Phase 1 trials in North America. The company announced data and development in relation to its first repurposed drug candidate, SACT-1, for the treatment of neuroblastoma, a rare form of cancer that develops in infants and young children. Subject to completion of current validation studies, Aptorum Group targets to leverage the US FDA 505 regulatory process pathway and make the IND submission for SACT-1 in the second half of 2020 and commence clinical trials in North America.

ShowHide Related Items >><<
Over a month ago
Conference/Events
Aptorum Group to host business news update conference call » 21:25
04/01/20
04/01
21:25
04/01/20
21:25
APM

Aptorum Group

$3.92 /

+0.18 (+4.81%)

Management discusses the…

Management discusses the progress of the Company's existing pipeline, including SACT-1 and ALS-4, and the latest announced project targeting the Coronavirus group, including COVID-19, on a conference call to be held on April 1 at 10 pm. Webcast Link

ShowHide Related Items >><<
APM Aptorum Group
$3.92 /

+0.18 (+4.81%)

04/02/19 China Renaissance
Aptorum Group initiated with a Buy at China Renaissance
Conference/Events
Aptorum Group to host business news update conference call » 04:55
04/01/20
04/01
04:55
04/01/20
04:55
APM

Aptorum Group

$3.74 /

+0.44 (+13.33%)

Management discusses the…

Management discusses the progress of the Company's existing pipeline, including SACT-1 and ALS-4, and the latest announced project targeting the Coronavirus group, including COVID-19, on a conference call to be held on April 1 at 10 pm. Webcast Link

ShowHide Related Items >><<
APM Aptorum Group
$3.74 /

+0.44 (+13.33%)

04/02/19 China Renaissance
Aptorum Group initiated with a Buy at China Renaissance
Conference/Events
Aptorum Group to host business news update conference call » 16:32
03/31/20
03/31
16:32
03/31/20
16:32
APM

Aptorum Group

$3.74 /

+0.44 (+13.33%)

Management discusses the…

Management discusses the progress of the Company's existing pipeline, including SACT-1 and ALS-4, and the latest announced project targeting the Coronavirus group, including COVID-19, on a conference call to be held on April 1 at 10 pm. Webcast Link

ShowHide Related Items >><<
APM Aptorum Group
$3.74 /

+0.44 (+13.33%)

04/02/19 China Renaissance
Aptorum Group initiated with a Buy at China Renaissance
Hot Stocks
Aptorum Group enters collaboration with Covar Pharmaceuticals » 08:11
03/30/20
03/30
08:11
03/30/20
08:11
APM

Aptorum Group

$2.85 /

-0.08 (-2.73%)

Aptorum Group announced…

Aptorum Group announced that it is initiating an additional research and development project targeting the coronavirus group and has completed initial screening under the Smart-ACT platform, a repurposed and new drug discovery platform, to select, out of more than 2,600 approved small drug molecules, at least 3 potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19. Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and has also entered into agreement with the University of Hong Kong's Microbiology Department to conduct further preclinical investigation of the selected candidates prior to seeking approval from regulatory agencies to initiate clinical trials on suitable candidates. In particular, Aptorum Group will focus on investigation of at least three small molecule drugs (collectively "SACT-COV19"), that have shown potential interference against two enzyme targets, namely, 3CL-Protease and RNA dependent RNA Polymerase, or RDRP, with both playing pivotal roles in COVID-19's replication cycle. Specifically, 3CL-Protease is believed to mediate viral replication and transcription functions through extensive proteolytic processing, while RDRP is an enzyme that is believed to catalyze the replication of viral RNA from its RNA template. These selected candidates will undergo further preclinical assessment on efficacy against COVID-19. Aptorum Group has filed patent applications on the above candidates. Aptorum Group will also seek additional collaborators globally for driving its development of SACT-COV19 initiatives forward and welcomes interested parties to contact us to discuss collaboration opportunities.

ShowHide Related Items >><<
APM Aptorum Group
$2.85 /

-0.08 (-2.73%)

04/02/19 China Renaissance
Aptorum Group initiated with a Buy at China Renaissance
Syndicate
Aptorum Group announces closing of $10M registered direct offering » 13:01
02/28/20
02/28
13:01
02/28/20
13:01
APM

Aptorum Group

$6.05 /

-0.1 (-1.63%)

Aptorum Group Limited…

Aptorum Group Limited announced the closing of a registered direct offering of 1,351,350 Class A ordinary shares at a per share offering price of $7.40. The investors also received accompanying warrants to purchase 1,351,350 of its Class A ordinary shares at an exercise price of $7.40 per share. Participation in the offering includes approximately $6M from unaffiliated institutional investors and $4M from Jurchen Investment Corporation, the largest shareholder of Aptorum Group, which is wholly owned by Ian Huen, the CEO and Executive Director of Aptorum Group. A.G.P./Alliance Global Partners acted as the lead placement agent and Maxim Group acted as co-placement agent for the offering. Aptorum Group received gross proceeds of $10M from the offering, before deducting underwriting discounts and offering expenses. Aptorum Group intends to use the net proceeds from the offering primarily to fund the continued research and development of our leading therapeutic candidates into their respective clinical phases and also to expand our discovery and development pipeline of the Smart-ACTTM orphan diseases platform, as well as for working capital, and for general corporate purposes.

ShowHide Related Items >><<
APM Aptorum Group
$6.05 /

-0.1 (-1.63%)

04/02/19 China Renaissance
Aptorum Group initiated with a Buy at China Renaissance
Over a quarter ago
Syndicate
Aptorum Group prices $10M registered direct offering » 10:11
02/26/20
02/26
10:11
02/26/20
10:11
APM

Aptorum Group

$6.91 /

-7.525 (-52.15%)

Aptorum Group Limited…

Aptorum Group Limited announced the pricing of a registered direct offering of 1.35M Class A ordinary shares and warrants to purchase 1.35M of its Class A ordinary shares at an exercise price of $7.40 per share. The combined purchase price for one Class A ordinary share and one warrant will be $7.40. The gross proceeds to Aptorum Group from the registered direct offering are expected to be approximately $10M, before deducting the placement agents' fees and other estimated offering expenses. Participation in the offering includes approximately $6M from unaffiliated institutional investors and $4M from Jurchen Investment Corporation, the largest shareholder of Aptorum Group, which is wholly owned by Ian Huen, the CEO of Aptorum Group. The offering is expected to close on February 28, subject to customary closing conditions. Alliance Global Partners is acting as lead placement agent and Maxim Group is acting as a co-placement agent in connection with this offering.

ShowHide Related Items >><<
APM Aptorum Group
$6.91 /

-7.525 (-52.15%)

04/02/19 China Renaissance
Aptorum Group initiated with a Buy at China Renaissance
Hot Stocks
Aptorum Group commercializes dioscorea opposita bioactive nutraceutical tablets » 06:10
02/24/20
02/24
06:10
02/24/20
06:10
APM

Aptorum Group

$14.45 /

-0.66 (-4.37%)

Aptorum Group announces…

Aptorum Group announces the commercialization of its dietary supplement for women undergoing menopause and experiencing related symptoms. The supplement is made with the bioactive ingredient extracted Chinese yam powder containing "DOI", which is Aptorum Group's non-hormonal approach intended to meet certain growing consumer nutritional trends and concerns. It is estimated that 1.2B women worldwide will be menopausal or postmenopausal by the year 20301. The global woman's health supplement market for menopausal symptoms is projected to reach over $50B by 2025 with a CAGR rate of 16.4%. Initially, the supplement will be commercialized and sold in Hong Kong; the company is seeking regulatory clearance to market the product in other major jurisdictions. As part of the commercialization, Aptorum Group, through its wholly-owned subsidiary Nativus Life Sciences Limited, entered into a regional distribution agreement with Multipak Limited, a Hong Kong based group that operates household brands, including the Luk Yu tea bag and other health related products. Through Multipak, Aptorum Group will be able to increase the accessibility of the product to a large consumer base regionally. The production of Aptorum Group's dioscorea opposita bioactive nutraceutical tablets has commenced production in Canada and will soon be marketed under the brand name NativusWell.

ShowHide Related Items >><<
APM Aptorum Group
$14.45 /

-0.66 (-4.37%)

04/02/19 China Renaissance
Aptorum Group initiated with a Buy at China Renaissance
Hot Stocks
Aptorum Group announces update on repurposed drug candidate SACT-1 » 08:07
02/10/20
02/10
08:07
02/10/20
08:07
APM

Aptorum Group

$14.51 /

-0.03 (-0.21%)

Aptorum Group announced…

Aptorum Group announced data and development in relation to its repurposed drug candidate, SACT-1, for the treatment of neuroblastoma, a rare type of childhood cancer that develops in infants and young children. Subject to completion of current validation studies, Aptorum Group plans to leverage the 505 pathway and submit an IND submission with the FDA for SACT-1 in H2 2020. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACTTM drug discovery platform, which employs a systematic approach to identify, repurpose and develop existing approved drugs against a currently identified universe of 7000+ orphan diseases. Through this platform, Aptorum Group intends to accelerate and fast track repurposed drug candidates, which usually have well established human safety and toxicity profiles and data, through the development and clinical phases in order to address the rapidly growing market of orphan diseases. Aptorum Group aims to screen a number of orphan disease areas including, but not limited to, oncology, autoimmune, metabolic and genetic diseases. Through the Smart-ACTTM platform, Aptorum has identified potential efficacy for and develops SACT-1 for the treatment of neuroblastoma, being an entirely new therapeutic area from its approved indication. In recent studies, SACT-1 has been shown to be effective against numerous neuroblastoma cell lines, of which 2 are MYCN-amplified cells, which represent the high-risk neuroblastoma patient group. In addition, by using a combination index as a quantitative measure of the extent of drug interaction, Aptorum Group has seen a high and robust synergism between SACT-1 and traditional chemotherapy in vitro, indicating a potential efficacy enhancement/dose reduction of the chemotherapy. In addition, in our recent study, the maximum tolerable dose of SACT-1 in a rodent model was determined to be higher than 400mg/kg. Compared with the MTD of standard chemotherapy such as paclitaxel and cisplatin, the safety profile of SACT-1 appears to be "impressive". The reformulation of SACT-1 is a pediatric formulation to better address the needs of neuroblastoma patients who are exclusively children younger than five. Based on our internal observations of pre-existing information from approved products, SACT-1 also exhibits a well-established safety profile: at 150mg/day, the death rate was 0% in prior clinical studies with no dosage related adverse events.

ShowHide Related Items >><<
APM Aptorum Group
$14.51 /

-0.03 (-0.21%)

04/02/19 China Renaissance
Aptorum Group initiated with a Buy at China Renaissance

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.